(Q36161966)

12 August 2017

1 reference

title

Oral effects of low-dose methotrexate treatment (English)

1 reference

12 August 2017

1 reference

Athanasios Kalantzis

1

1 reference

12 August 2017

Zoe Marshman

2

1 reference

12 August 2017

Denis T Falconer

3

1 reference

12 August 2017

Peter R Morgan

4

1 reference

12 August 2017

Edward W Odell

5

1 reference

12 August 2017

1 July 2005

1 reference

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

12 August 2017

1 reference

12 August 2017

100

1 reference

12 August 2017

1

1 reference

12 August 2017

52-62

1 reference

Methotrexate use in rheumatoid arthritis. A Clinician's perspective

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate for treating juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Current treatment of juvenile rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Risk-benefit assessment of methotrexate in the treatment of severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Interventions for psoriatic arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis i

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate therapy in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Localized and systemic scleroderma show different histological responses to methotrexate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Use of methotrexate in the management of sight-threatening uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Mechanisms of action of methotrexate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

The remarkable spectrum of methotrexate toxicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

[Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Errors in prescribing methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Rheumatoid arthritis and osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Infections during low-dose methotrexate treatment in rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Does methotrexate increase the risk of infection or malignancy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Hazards of low dose methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

The incidence of cancer associated with the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Studies on the Biology of the Periodontium of Marmosets: VIII. The Effect of Folic Acid Deficiency on the Marmoset Oral Mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Effect of long-term methotrexate-induced neutropenia on experimental periodontal lesion in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Survival, prognosis, and causes of death in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Progress in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal women with dietary changes in folate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Localized deficiencies of folic acid in aerodigestive tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Nuclear characteristics of buccal mucosa cells in sickle-cell anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Bizarre epithelial atypia of the sinonasal tract after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Immunosuppression-associated lymphoproliferative disorders in rheumatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Weekly intravenous methotrexate in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

Advances in the medical management of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2004.08.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRIPLEO.2004.08.020

1 reference

12 August 2017

1 reference